CompletedNot Applicable

Competitive Revision for CLARO: Collaboration Leading to Addiction Treatment and Recovery From Other Stresses

United States68 participantsStarted 2022-08-31

Plain-language summary

The purpose of this study is to develop and then test an enhanced version of the parent study's collaborative care intervention for co-occurring disorders (CC-COD) to reduce the risk of suicide and overdose among individuals with opioid use disorder (OUD) in combination with PTSD/depression. The parent study is CLARO, Collaboration Leading to Addiction Treatment and Recovery from Other Stresses (NCT04559893).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 and older * Receiving primary care at one of the participating clinical sites * Has OUD and one or more specific co-occurring behavioral health disorders (depression and PTSD) Exclusion Criteria: * Under 18 * Does not speak English or Spanish * Unable to consent * Receiving both MOUD and psychotropic medication from a provider outside of the primary care health system at which the patient is enrolled. * Not receiving primary care at one of the participating clinical sites

What they're measuring

MOUD continuity of care

Timeframe: Assessed over the first 180 days after study entry

Trial details

NCT IDNCT04634279

SponsorRAND

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-12

View on ClinicalTrials.gov More Opioid-use Disorder trials